Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles W Locuson

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|February 22, 2007
Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9Charles W Locuson, Peter M Gannett, Robyn Ayscue, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2008
In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibitionDivesh Aidasani, Matthew J Zaya, Phyllis B Malpas, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 21, 2007
CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysisCharles W Locuson, Larry C Wienkers, Jeffrey P Jones, et al.
Molecular Pharmacology|March 27, 2004
Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9Leslie J Dickmann, Charles W Locuson, Jeffrey P Jones, et al.
Journal of Veterinary Pharmacology and Therapeutics|February 21, 2016
Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesiaPatty H Chen, Kelli L Boyd, Erin K Fickle, et al.
American Journal of Veterinary Research|July 24, 2020
Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogsButch KuKanich, Kate KuKanich, David C Rankin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 17, 2008
Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductaseCharles W Locuson, Brian T Ethell, Michael Voice, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 7, 2018
Comparison of predicted intrinsic hepatic clearance of 30 pharmaceuticals in canine and feline liver microsomesMarike Visser, Matthew J Zaya, Charles W Locuson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2003
A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivativesCharles W Locuson, Jan L Wahlstrom, Denise A Rock, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 16, 2011
Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogsStewart T Dunn, Laura Hedges, Kathleen E Sampson, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|February 22, 2007
Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9Charles W Locuson, Peter M Gannett, Robyn Ayscue, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2008
In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibitionDivesh Aidasani, Matthew J Zaya, Phyllis B Malpas, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 21, 2007
CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysisCharles W Locuson, Larry C Wienkers, Jeffrey P Jones, et al.
Molecular Pharmacology|March 27, 2004
Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9Leslie J Dickmann, Charles W Locuson, Jeffrey P Jones, et al.
Journal of Veterinary Pharmacology and Therapeutics|February 21, 2016
Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesiaPatty H Chen, Kelli L Boyd, Erin K Fickle, et al.
American Journal of Veterinary Research|July 24, 2020
Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogsButch KuKanich, Kate KuKanich, David C Rankin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 17, 2008
Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductaseCharles W Locuson, Brian T Ethell, Michael Voice, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 7, 2018
Comparison of predicted intrinsic hepatic clearance of 30 pharmaceuticals in canine and feline liver microsomesMarike Visser, Matthew J Zaya, Charles W Locuson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2003
A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivativesCharles W Locuson, Jan L Wahlstrom, Denise A Rock, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 16, 2011
Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogsStewart T Dunn, Laura Hedges, Kathleen E Sampson, et al.
Pageof 4